[go: up one dir, main page]

DK2931030T4 - Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse - Google Patents

Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse Download PDF

Info

Publication number
DK2931030T4
DK2931030T4 DK13843056.6T DK13843056T DK2931030T4 DK 2931030 T4 DK2931030 T4 DK 2931030T4 DK 13843056 T DK13843056 T DK 13843056T DK 2931030 T4 DK2931030 T4 DK 2931030T4
Authority
DK
Denmark
Prior art keywords
graver
antibodies
animals
polynucleotides encoding
human idiotypes
Prior art date
Application number
DK13843056.6T
Other languages
English (en)
Other versions
DK2931030T3 (da
Inventor
Marianne Bruggemann
Roland Buelow
Michael J Osborn
Biao Ma
Original Assignee
Omniab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50935093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2931030(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omniab Inc filed Critical Omniab Inc
Application granted granted Critical
Publication of DK2931030T3 publication Critical patent/DK2931030T3/da
Publication of DK2931030T4 publication Critical patent/DK2931030T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK13843056.6T 2012-12-14 2013-12-13 Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse DK2931030T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737371P 2012-12-14 2012-12-14
PCT/US2013/075157 WO2014093908A2 (en) 2012-12-14 2013-12-13 Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same

Publications (2)

Publication Number Publication Date
DK2931030T3 DK2931030T3 (da) 2020-08-03
DK2931030T4 true DK2931030T4 (da) 2024-04-22

Family

ID=50935093

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13843056.6T DK2931030T4 (da) 2012-12-14 2013-12-13 Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse
DK19204021.0T DK3653049T5 (da) 2012-12-14 2013-12-13 Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19204021.0T DK3653049T5 (da) 2012-12-14 2013-12-13 Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse

Country Status (20)

Country Link
US (2) US9475859B2 (da)
EP (3) EP3653049B1 (da)
JP (1) JP6705650B2 (da)
KR (3) KR20220041953A (da)
CN (2) CN110042105B (da)
AU (2) AU2013358958B2 (da)
CA (1) CA2895144C (da)
CY (1) CY1123215T1 (da)
DK (2) DK2931030T4 (da)
ES (2) ES2813609T5 (da)
FI (2) FI3653049T3 (da)
HR (2) HRP20201160T4 (da)
HU (2) HUE064063T2 (da)
IL (2) IL239300B (da)
LT (2) LT3653049T (da)
PL (2) PL3653049T3 (da)
PT (2) PT2931030T (da)
SG (1) SG11201504676VA (da)
SI (2) SI3653049T1 (da)
WO (1) WO2014093908A2 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008548A2 (en) 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
US10993420B2 (en) * 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
KR20170073647A (ko) * 2014-10-22 2017-06-28 크레센도 바이오로직스 리미티드 형질전환 마우스
US11326184B2 (en) * 2014-12-19 2022-05-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification through single-step multiple targeting
JP7049988B2 (ja) 2015-08-05 2022-04-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ１５４抗体及びこれを使用する方法
AU2016308567B2 (en) 2015-08-17 2022-10-27 Janssen Biotech, Inc. Anti-BCMA antibodies, bispecific antigen binding molecules that bind BCMA and CD3, and uses thereof
MA43053A (fr) 2015-09-30 2018-08-08 Janssen Biotech Inc Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
US20170121420A1 (en) 2015-11-02 2017-05-04 Janssen Pharmaceutica Nv Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
JP7053499B2 (ja) 2016-06-03 2022-04-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物
BR112018076767A2 (pt) * 2016-06-21 2019-04-02 Teneobio, Inc. anticorpos de ligação a cd3
DK4050034T3 (da) * 2016-09-14 2024-06-03 Teneoone Inc Cd3-bindende antistoffer
AU2017365367B2 (en) * 2016-11-22 2024-09-19 Merck Patent Gmbh Monoclonal antibody directed to FGFR1
WO2018095932A1 (en) * 2016-11-22 2018-05-31 Merck Patent Gmbh Monoclonal antibody directed to fgfr1
CN118140872A (zh) 2017-01-19 2024-06-07 欧莫诺艾比公司 来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体
KR102742528B1 (ko) 2017-06-20 2024-12-16 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
CN111683966B (zh) * 2017-12-22 2023-07-11 特尼奥生物股份有限公司 与cd22结合的重链抗体
US11591399B2 (en) 2018-02-14 2023-02-28 Abba Therapeutics Ag Anti-human PD-L2 antibodies
LT3772927T (lt) 2018-03-24 2025-02-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės arba žiurkės, skirtos gaminti terapinius antikūnus prieš peptidų- mhc kompleksus, jų gamybos būdai ir panaudojimas
JP7411575B2 (ja) 2018-05-11 2024-01-11 ウーシー・バイオロジクス・（シャンハイ）・カンパニー・リミテッド Ｏｘ４０に対する完全ヒト抗体、それを調製する方法、およびその使用
JP7395508B2 (ja) 2018-05-16 2023-12-11 ヤンセン バイオテツク，インコーポレーテツド 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
US11603405B2 (en) 2018-05-24 2023-03-14 Janssen Biotech, Inc. Anti-CD3 antibodies and uses thereof
MA52772A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
AU2020226445A1 (en) 2019-02-18 2021-07-08 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
WO2020206330A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
JP2022537931A (ja) 2019-06-14 2022-08-31 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
CA3147735A1 (en) 2019-07-26 2021-02-04 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
PE20220259A1 (es) 2019-07-26 2022-02-21 Janssen Biotech Inc Receptor de antigeno quimerico (car) anti-hk2
US11760801B2 (en) 2019-09-27 2023-09-19 Janssen Biotech, Inc. Anti-CEACAM antibodies and uses thereof
MX2022004098A (es) 2019-10-03 2022-07-19 Janssen Biotech Inc Métodos para producir productos bioterapéuticos con estabilidad aumentada mediante optimización de secuencias.
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
AU2021263448A1 (en) 2020-04-29 2022-11-24 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
TW202208429A (zh) 2020-05-11 2022-03-01 比利時商健生藥品公司 用於治療多發性骨髓瘤之方法
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
IL298632A (en) 2020-06-02 2023-01-01 Biocytogen Pharmaceuticals Beijing Co Ltd Genetically modified non-human animals with common light chain immunoglobulin locus
US11827708B2 (en) 2020-07-29 2023-11-28 Janssen Biotech, Inc. Proteins comprising HLA-G antigen binding domains and their uses
JP2023540808A (ja) 2020-09-11 2023-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗原特異的抗体の同定及び産生
US20240065239A1 (en) 2020-12-16 2024-02-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
AU2021410655A1 (en) 2020-12-23 2023-06-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
AU2022213825A1 (en) 2021-01-27 2023-09-14 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
AU2022380722A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
WO2023144723A1 (en) 2022-01-26 2023-08-03 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
AR130536A1 (es) 2022-09-21 2024-12-18 Seagen Inc Anticuerpos que se unen a cd228
TW202428603A (zh) 2022-09-21 2024-07-16 美商思進公司 新穎的cd137及cd228特異性融合蛋白

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
US5411881A (en) 1990-07-10 1995-05-02 Nkk Corporation Chicken-specific immunoglobulin G-producing hybridoma
DE69127627T2 (de) * 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
JPH08140528A (ja) * 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
AU7326796A (en) 1995-10-30 1997-05-22 Spectral Diagnostics Inc. Stable chicken b-cell line and method of use thereof
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
JP4215172B2 (ja) * 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
WO2006008548A2 (en) 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
CA2585098C (en) * 2004-10-22 2018-12-18 Revivicor, Inc. Porcine genomic kappa and lambda light chain sequences
RU2435784C2 (ru) 2006-01-25 2011-12-10 Эрасмус Юниверсити Медикал Сентр Роттердам Получение антител из одних тяжелых цепей в трансгенных животных
JP5514539B2 (ja) * 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
SG10201509853UA (en) * 2007-06-01 2015-12-30 Omt Inc Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
EP3871497B1 (en) * 2009-07-08 2024-02-28 Kymab Limited Rodent models and therapeutic molecules
AU2011266843C9 (en) * 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination

Also Published As

Publication number Publication date
DK3653049T3 (da) 2023-11-13
SI3653049T1 (sl) 2024-02-29
HUE050930T2 (hu) 2021-01-28
HUE064063T2 (hu) 2024-02-28
CY1123215T1 (el) 2021-12-31
JP6705650B2 (ja) 2020-06-03
EP4269602A2 (en) 2023-11-01
IL239300B (en) 2021-01-31
US10385132B2 (en) 2019-08-20
JP2016505257A (ja) 2016-02-25
EP2931030B2 (en) 2024-01-17
PT3653049T (pt) 2023-11-14
KR102239125B1 (ko) 2021-04-12
NZ749259A (en) 2020-09-25
EP3653049A1 (en) 2020-05-20
EP3653049B1 (en) 2023-09-13
ES2813609T5 (es) 2024-08-09
EP4269602A3 (en) 2023-12-27
AU2013358958B2 (en) 2018-09-20
PT2931030T (pt) 2020-08-03
PL2931030T5 (pl) 2024-06-10
SG11201504676VA (en) 2015-07-30
CN110042105A (zh) 2019-07-23
KR20150094720A (ko) 2015-08-19
AU2018223041A1 (en) 2018-09-20
EP2931030B1 (en) 2020-04-29
US20150113668A1 (en) 2015-04-23
AU2018223041B2 (en) 2020-06-25
FI2931030T4 (fi) 2024-04-22
CA2895144A1 (en) 2014-06-19
AU2013358958A1 (en) 2015-07-09
NZ709608A (en) 2020-09-25
LT3653049T (lt) 2023-11-10
CN104994729B (zh) 2019-01-11
SI2931030T2 (sl) 2024-06-28
LT2931030T (lt) 2020-11-10
PL3653049T3 (pl) 2024-02-26
CA2895144C (en) 2024-04-16
IL239300A0 (en) 2015-07-30
PL2931030T3 (pl) 2021-03-22
WO2014093908A2 (en) 2014-06-19
CN110042105B (zh) 2023-03-28
WO2014093908A3 (en) 2014-10-16
HRP20231356T1 (hr) 2024-02-16
DK2931030T3 (da) 2020-08-03
FI3653049T3 (fi) 2023-11-02
HRP20201160T1 (hr) 2020-12-11
US20170174770A1 (en) 2017-06-22
ES2963516T3 (es) 2024-03-27
DK3653049T5 (da) 2024-08-26
SI2931030T1 (sl) 2020-10-30
IL279716A (en) 2021-01-31
ES2813609T3 (es) 2021-03-24
KR20210040189A (ko) 2021-04-12
KR20220041953A (ko) 2022-04-01
HRP20201160T4 (hr) 2024-10-11
CN104994729A (zh) 2015-10-21
US9475859B2 (en) 2016-10-25
EP2931030A2 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
DK2931030T4 (da) Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse
CL2015001924A1 (es) Anticuerpos anti-pdgfr-beta y usos relacionados.
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK3308641T3 (da) Immundeficient genmodificeret gnaver og fremgangsmåder til anvendelse deraf
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK2970460T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
BR112014029053A2 (pt) disposição de escovação e método de operação de disposição de escovação animal.
LT3473714T (lt) Polipeptidai, pasižymintys transgalaktozilinimo aktyvumu
EP2814953A4 (en) POLYMERASE ENZYME SUBSTRATES HAVING A PROTEIN SHIELD
DK3071593T3 (da) Modificerede humane t-celle-receptorer med høj affinitet
BR112014032227A2 (pt) dispositivo e método de decodificação.
HUE049012T2 (hu) Antitestek S. aureus felszíni determinánsok ellen
EP2863736A4 (en) GENETICALLY MODIFIED ANIMALS AND METHODS OF PRODUCTION THEREFOR
BR302013006798S1 (pt) Configuração aplicada em halter.
EP2922564A4 (en) ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS
PL3004167T3 (pl) Białka wiążące antygen receptora onkostatyny m
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
HUE053561T2 (hu) Állatõrzõ kerítés és eljárás annak összeszerelésére
DK3434614T3 (da) Aftageligt dækningsapparat med flere dele og tilhørende
BR112014004128A2 (pt) dispositivo e método de decodificação, dispositivo e método de codificação, e, programa
BR112014004127A2 (pt) dispositivo e método de decodificação, programa, e, dispositivo e método de codificação
DK3016547T3 (da) Dyrebarriere og fremgangsmåde
DK2895600T3 (da) Ube2t-peptider og vacciner, der indeholder disse
DK2814843T3 (da) IL-ß-NEUTRALISERENDE HUMANE MONOKLONALE ANTISTOFFER